<DOC>
	<DOCNO>NCT02876211</DOCNO>
	<brief_summary>Anemia inflammation ( AI ) common comorbidity hemodialysis patient . Paricalcitol selective vitamin D receptor activator potential benefit anti-inflammatory cytokine expression . The paricalcitol secondary hyperparathyroidism control may improve AI decrease erythropoietin stimulate agent ( ESAs ) dosage .</brief_summary>
	<brief_title>Paricalcitol Improves Anemia Inflammation</brief_title>
	<detailed_description>Anemia inflammation secondary hyperparathyroidism ( SHPT ) two common clinical complication patient chronic kidney disease . Eryptosis ( accelerate red blood cell death ) novel mechanism associate renal anemia several factor u iron , erythropoietin klotho ( anti-aging hormone ) deficiency associate process . The use paricalcitol may inhibit pro-inflammatory cytokine expression , especially interleukine-6 , one important cytokine associate pathogenesis AI . If use paricalcitol SHPT control may exert direct influence erythropoiesis process know .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<mesh_term>Hematinics</mesh_term>
	<criteria>Age &gt; = 18 year . Patients CKD hemodialysis etiology.. Hemoglobin 10 12g/dl least 12 week enrollment study . Hemoglobin plasma level stabilize : Hb variation &lt; = 1 g / dl two month prior inclusion study . Patients anemia renal etiology . ESA treatment stable dose 2 month prior baseline.Stable dose ESA Definition : Variation &lt; = 3000UI/week . Iron status : Ferritin &gt; 200 ng / mL transferrin saturation index ( IST ) : &gt; = 30 % ) . KT / V &gt; = 1.2 ( Daugirdas2nd generation ) . Calcium concentration : 8.4 9.5 mg / dl phosphorus : 3.55.5 mg / dl . Vitamin D 25OH normal &gt; = 15 ng / ml ( patient low level supplement calcifediol 16000 IU / biweekly 6 week select patient ) . PTHi concentration &gt; = 150 pg / mL &lt; = 300 pg / ml . Patients accept inclusion study sign inform consent . Epoetin beta dose &gt; 18,000 IU / weekly . Pregnant woman childbearing age gestational wish use adequate contraception ( OginoKnaus contraceptive method consider unsuitable ) . Active bleeding episode history transfusion 2 month prior baseline . Patients nonrenal cause anemia : malignancy , folic acid vitamin B12 deficiency , hemoglobinopathy , hemolysis , pure red cell aplasia secondary erythropoietin . Patients treat selective vitamin D receptor activator 3 month prior inclusion study . Acute chronic symptomatic : heart failure ( IVNYHA ) , infection inflammatory disease , uncontrolled hypertension require suspension epoetin beta , thrombocytopathies , aplastic anemia . Immunosuppressive treatment uncontrolled Hemoglobin level Allergy paricalcitol component .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Renal disease</keyword>
	<keyword>Erythropoiesis</keyword>
	<keyword>Erythropoietin stimulating agent</keyword>
	<keyword>Iron</keyword>
	<keyword>Klotho</keyword>
	<keyword>Selective vitamin D receptor activation</keyword>
</DOC>